MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

TG Therapeutics Inc

Fechado

SetorSaúde

39.82 6.21

Visão Geral

Variação de preço das ações

24h

Atual

Mín

36.96

Máximo

41.97

Indicadores-chave

By Trading Economics

Rendimento

19M

23M

Vendas

24M

108M

P/E

Médio do Setor

262.867

63.778

EPS

0.15

Margem de lucro

21.566

Funcionários

338

EBITDA

17M

33M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+7.48% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.4B

6.3B

Abertura anterior

33.61

Fecho anterior

39.82

Sentimento de Notícias

By Acuity

61%

39%

336 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

19 de ago. de 2024, 20:01 UTC

Ganhos

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

7.48% parte superior

Previsão para 12 meses

Média 42.8 USD  7.48%

Máximo 55 USD

Mínimo 10 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

5

Comprar

0

Manter

1

Vender

Pontuação Técnica

By Trading Central

39.43 / 42.8Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

336 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.